-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Moderna, Raises Price Target to $150

Benzinga·08/20/2026 15:55:02
語音播報
UBS analyst Michael Yee maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $50 to $150.